Genprex announced that its Senior Director of Quality Control & Product Development, Dr. Pier-Anne Lachance, will present insights on two parallel gene delivery methods—AAV-based and lipid-based—for diabetes therapy at the Drug Discovery News symposium. These approaches aim to restore insulin production in diabetes patients and are currently in preclinical stages. The presentation highlights Genprex's efforts to optimize gene therapy delivery and manufacturing, which could influence future treatment strategies. This event underscores Genprex's commitment to advancing innovative gene therapies for diabetes and cancer.
Genprex's dual gene delivery strategy for diabetes therapy is the subject, with Pluang's health sector market data providing context. Of 150 priced health-sector US stocks on Pluang, 67 rose and 75 fell today. Notable movers include InMode Ltd (INMD) at USD 13.85 with a 4.41% gain and Alcon AG (ALC) at USD 70.89 with a 4.28% decline, as of Nov 11, 2026 19:11 WIB.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
